Get started
Author

Raphael Brandão Moreira

Observed names: R. Brandao, Raphael B. Moreira, Raphael Brandao, Raphael Brandao Moreira, Raphael Brandão, Raphael Moreira
Observed institutions: Brigham and Women's Hospital, Harvard University, University of Florida, Hospital de São José, Hospital Samaritano de São Paulo, Hospital Alemão Oswaldo Cruz, São Camilo Hospital, Fundação Educacional D. André Arcoverde, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center, Hospital São Paulo
ORCID: 0000-0002-7464-5544
Observed ORCID: 0000-0002-7464-5544
OpenAlex ID: A5082537363
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
2017 · Guillermo De Velasco, Youjin Je, et al. · Cancer Immunology Research · 500
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
2018 · Rana R. McKay, Dominick Bossé, et al. · Cancer Immunology Research · 130
PDF
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
2017 · Raphael B. Moreira, Marcio Debiasi, et al. · Oncotarget · 89
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
2018 · Steven M. Yip, Connor Wells, et al. · Cancer · 69
PDF
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
2018 · Dylan J. Martini, Lana Hamieh, et al. · Cancer Immunology Research · 63
The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort
2018 · Maxine Sun, Guillermo De Velasco, et al. · European Urology Focus · 57
Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis
2017 · Lauren C. Harshman, Wanling Xie, et al. · Cancer · 45
Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
2016 · Lana Hamieh, Rana R. McKay, et al. · Clinical Genitourinary Cancer · 33
Cancer Immunotherapy Principles and Practice
2017 · Lisa H. Butterfield, Howard L. Kaufman, et al. · Springer Publishing Company eBooks · 30
Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases
2018 · Jessica Tsukamoto, Mariana Monteiro, et al. · Case Reports in Oncology · 27
Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification
2015 · Raphael Brandão Moreira, Renata D''Alpino Peixoto, et al. · Case Reports in Oncology · 24
The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases
2017 · Mariuxi A. Viteri Malone, Gustavo Ruiz Ares, et al. · Clinical Genitourinary Cancer · 19
Disappearing colorectal liver metastases: Strategies for the management of patients achieving a radiographic complete response after systemic chemotherapy
2019 · Raphael L. C. Araujo, Jean Michel Milani, et al. · Journal of Surgical Oncology · 18
The management of immune-related adverse events associated with immune checkpoint blockade
2016 · André P. Fay, Raphael Brandão Moreira, et al. · Expert Review of Quality of Life in Cancer Care · 17
PDF
Low-Dose Bevacizumab Is Effective in Radiation-Induced Necrosis
2013 · Matheus Alessandretti, Antonio Carlos Buzaid, et al. · Case Reports in Oncology · 17
Palliative Prognostic Index accuracy of survival prediction in an inpatient palliative care service at a Brazilian tertiary hospital
2021 · Mauricio Fernandes, Tago Pugliese Branco, et al. · ecancermedicalscience · 14
PDF
Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.
2017 · Steven Yip, Connor Wells, et al. · Journal of Clinical Oncology · 13
Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).
2017 · Raphael Brandao Moreira, Rana R. McKay, et al. · Journal of Clinical Oncology · 12
Perfil clínico-demográfico e indicadores de qualidade da insuficiência cardíaca em uma área rural
2009 · Henrique Miller Balieiro, Raphael Kasuo Osugue, et al. · Arquivos Brasileiros de Cardiologia · 12
PDF
Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).
2017 · Jean-Christophe Pignon, Opeyemi Jegede, et al. · Journal of Clinical Oncology · 10
Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC).
2017 · Rana R. McKay, Dylan Martini, et al. · Journal of Clinical Oncology · 9
Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials.
2016 · Raphael Brandao Moreira, Marcio Debiasi, et al. · Journal of Clinical Oncology · 8
Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma.
2015 · Matheus Bongers Alessandretti, Raphael Brandao Moreira, et al. · Journal of Clinical Oncology · 7
A large-scale, multi-centre validation study of an AI-empowered blood-based test for multi-cancer early detection
2025 · Yong Shen, Yong Xia, et al. · npj Precision Oncology · 5
PDF
Body mass index and immune checkpoint inhibitor efficacy in metastatic cancer patients: A Brazilian retrospective study
2022 · Raphael Brandao Moreira, Mauricio Fernandes, et al. · Frontiers in Urology · 5
PDF
Works count: 68
Citation count: 1,276
H-index: 15
I10-index: 20
Year
Topic
Type